1073545-86-4

Basic information

• Product Name: 5-(cyclopropyl(4-hydroxyphenyl)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione
• Synonyms: 5-(cyclopropyl(4-hydroxyphenyl)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione
• CAS NO: 1073545-86-4
• Molecular Weight: 290.316
• Mol File: 1073545-86-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-(cyclopropyl(4-hydroxyphenyl)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(cyclopropyl(4-hydroxyphenyl)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione(1073545-86-4)
• EPA Substance Registry System: 5-(cyclopropyl(4-hydroxyphenyl)methyl)-2,2-dimethyl-1,3-dioxane-4,6-dione(1073545-86-4)

Safety Data

• Hazardous Substances Data: 1073545-86-4(Hazardous Substances Data)

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 17474-27-0 5-(4-hydroxy-benzylidene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 23719-80-4 cyclopropylmagnesium bromide 

Downstream Products

• 1073543-98-2 (3S)-3-cyclopropyl-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)propanoic acid 
• 1073543-99-3 (3R)-3-cyclopropyl-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)propanoic acid 
• 1073545-97-7 methyl (3S)-3-cyclopropyl-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)propanoate 
• 1073545-99-9 methyl (3R)-3-cyclopropyl-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)propanoate 
• 1073545-95-5 (R)-methyl 3-cyclopropyl-3-(4-hydroxyphenyl)propanoate 
• 1073545-93-3 (S)-methyl 3-cyclopropyl-3-(4-hydroxyphenyl)propanoate 
• 1073545-90-0 3-cyclopropyl-3-(4-hydroxyphenyl)propanoic acid methyl ester 
• 1073545-88-6 3-cyclopropyl-3-(4-hydroxyphenyl)propanoic acid 

Relevant articles and documents

ANTIDIABETIC BICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.